Immuron (IMRN) Non Operating Interest Expenses (2017 - 2025)
Immuron (IMRN) posted Non Operating Interest Expenses of -$4678.4 for Q2 2025, down 9167.48% on a QoQ basis from -$50.48 in Q3 2024, and up 6.3% year-over-year from -$4401.2 in Q2 2024.
Analysis
Immuron (IMRN) Non Operating Interest Expenses (2017 - 2025) Analysis & Trends
Immuron has reported Non Operating Interest Expenses for 8 years, with the latest figure at -$4678.4 in Q2 2025.
- On a quarterly basis, Non Operating Interest Expenses rose 6.3% year-over-year to -$4678.4 in Q2 2025; TTM through Jun 2025 was -$16005.0, a 135.9% decrease from a year earlier, with the FY2026 full-year figure at -$14712.0, down 20039.63% from the prior year.
- Non Operating Interest Expenses was -$4678.4 for Q2 2025 at Immuron, down from -$50.48 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $4501.0 in Q4 2022, with the low at -$10596.7 in Q2 2021.
- Average Non Operating Interest Expenses over 5 years is -$3158.6, with a median of -$4678.4 recorded in 2025.
- The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses surged 47253.03% in 2022, then plunged 239.6% in 2023.
- Over 5 years, Non Operating Interest Expenses stood at -$9.55 in 2021, then soared by 47253.03% to $4501.0 in 2022, then slumped by 239.6% to -$6283.4 in 2023, then jumped by 99.2% to -$50.48 in 2024, then plunged by 9167.48% to -$4678.4 in 2025.
- The last three Non Operating Interest Expenses figures came in at -$4678.4 (Q2 2025), -$50.48 (Q3 2024), and -$4992.8 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Immuron | 10.28 Mn | 1.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -4,678.36 |
| Sep 9, 2024 | -50.48 |
| Jun 30, 2024 | -4,992.77 |
| Dec 31, 2023 | -6,283.36 |
| Dec 31, 2022 | 4,501.00 |
| Dec 31, 2021 | -9.55 |
| Jun 30, 2021 | -10,596.73 |
| Dec 31, 2020 | -58.04 |
| Jun 30, 2020 | -14,177.40 |
| Dec 31, 2019 | -23.46 |
| Dec 31, 2017 | -2,896.97 |